Drugging multiple same-allele driver mutations in cancer

References

• Martincorena I, Raine KM, Gerstung M, et al. Universal Patterns of Selection in Cancer and Somatic Tissues. Cell. 2017 Nov 16;171(5):1029–1041 e21.
   PubMed Web of Science ®Google Scholar
• Nussinov R, Tsai CJ, Jang H. Are Parallel Proliferation Pathways Redundant? Trends Biochem Sci. 2020 Jul;45(7):554–563.
   PubMed Web of Science ®Google Scholar
• You I, Erickson EC, Donovan KA, et al. Discovery of an AKT Degrader with Prolonged Inhibition of Downstream Signaling. Cell Chem Biol. 2020 Jan 16;27(1):66–73 e7.
   PubMed Web of Science ®Google Scholar
• Vasan N, Razavi P, Johnson JL, et al. Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3K alpha inhibitors. Science. 2019 Nov 8;366(6466):714–723.
   PubMed Web of Science ®Google Scholar
• Saito Y, Koya J, Araki M, et al. Landscape and function of multiple mutations within individual oncogenes. Nature. 2020 Jun;582(7810):95–99.
   PubMed Web of Science ®Google Scholar
• Zhang M, Jang H, Nussinov R. PI3K driver mutations: a biophysical membrane-centric perspective. Cancer Res. 2020. 10.1158/0008-5472.CAN-20-0911
   Web of Science ®Google Scholar
• Nussinov R, Tsai CJ, Jang H. Why are some driver mutations rare? Trends Pharmacol Sci. 2019 Dec;40(12):919–929.
   PubMed Web of Science ®Google Scholar
• Brown AL, Li M, Goncearenco A, et al. Finding driver mutations in cancer: elucidating the role of background mutational processes. PLoS Comput Biol. 2019 Apr;15(4):e1006981.
   PubMed Web of Science ®Google Scholar
• Poulin EJ, Bera AK, Lu J, et al. Tissue-specific oncogenic activity of KRAS A146T. Cancer Discov. 2019 Jun;9(6):738–755.
   PubMed Web of Science ®Google Scholar
• Tan ZW, Guarnera E, Tee WV, et al. AlloSigMA 2: paving the way to designing allosteric effectors and to exploring allosteric effects of mutations. Nucleic Acids Res. 2020 Jul 2;48(W1):W116–W124.
   PubMed Web of Science ®Google Scholar
• Xue JM, Liu Y, Wan LH, et al. Comprehensive analysis of differential gene expression to identify common gene signatures in multiple cancers. Med Sci Monit. 2020 Feb;8(26):e919953.
   Google Scholar
• Souza-Santos PT, Soares Lima SC, Nicolau-Neto P, et al. Mutations, differential gene expression, and chimeric transcripts in esophageal squamous cell carcinoma show high heterogeneity. Transl Oncol. 2018 Dec;11(6):1283–1291.
   PubMed Web of Science ®Google Scholar
• Burke JE, Perisic O, Masson GR, et al. Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110alpha (PIK3CA). Proc Natl Acad Sci U S A. 2012 Sep 18;109(38):15259–15264.
   PubMed Web of Science ®Google Scholar
• Huang CH, Mandelker D, Schmidt-Kittler O, et al. The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science. 2007 Dec 14;318(5857):1744–1748.
   PubMed Web of Science ®Google Scholar
• Zhang M, Jang H, Nussinov R. The mechanism of PI3Kalpha activation at the atomic level. Chem Sci. 2019Mar28;10(12):3671–3680.
   PubMed Web of Science ®Google Scholar
• Chakrabarti M, Gabelli SB, Amzel LM. Allosteric activation of PI3Kalpha results in dynamic access to catalytically competent conformations. Structure. 2020 Apr 7;28(4):465–474 e5.
   PubMed Web of Science ®Google Scholar
• Tangye SG. Defects in human B-cell development and differentiation due to disease-causing mutations in the Pi3k pathway. J Clin Immunol. 2016 Apr;36(3):298–299.
   Web of Science ®Google Scholar
• Nussinov R, Zhang M, Tsai CJ, et al. Phosphorylation and driver mutations in PI3Kalpha and PTEN autoinhibition. Mol Cancer Res. 2020 Dec;7. DOI:10.1158/1541-7786.MCR-20-0818
   Web of Science ®Google Scholar
• Sun M, Hillmann P, Hofmann BT, et al. Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha. Proc Natl Acad Sci U S A. 2010 Aug 31;107(35):15547–15552.
   PubMed Web of Science ®Google Scholar
• Anandapadamanaban M, Masson GR, Perisic O, et al. Architecture of human Rag GTPase heterodimers and their complex with mTORC1. Science. 2019 Oct 11;366(6462):203–210.
   PubMed Web of Science ®Google Scholar
• Rogala KB, Gu X, Kedir JF, et al. Structural basis for the docking of mTORC1 on the lysosomal surface. Science. 2019 Oct 25;366(6464):468–475.
   PubMed Web of Science ®Google Scholar
• Chan KT, Blake S, Zhu H, et al. A functional genetic screen defines the AKT-induced senescence signaling network. Cell Death Differ. 2020 Feb;27(2):725–741.
   PubMed Web of Science ®Google Scholar
• Bailey MH, Tokheim C, Porta-Pardo E, et al. Comprehensive characterization of cancer driver genes and mutations. Cell. 2018 Apr 5;173(2):371–385 e18.
   PubMed Web of Science ®Google Scholar
• Bera AK, Lu J, Wales TE, et al. Structural basis of the atypical activation mechanism of KRAS(V14I). J Biol Chem. 2019 Sep 20;294(38):13964–13972.
   PubMed Web of Science ®Google Scholar
• Jiang W, Li H, Liu X, et al. Precise and efficient silencing of mutant Kras(G12D) by CRISPR-CasRx controls pancreatic cancer progression. Theranostics. 2020;10(25):11507–11519.
   PubMed Web of Science ®Google Scholar
• Lu J, Bera AK, Gondi S, et al. KRAS Switch Mutants D33E and A59G Crystallize in the State 1 Conformation. Biochemistry. 2018 Jan 23;57(3):324–333.
   PubMed Web of Science ®Google Scholar
• Martinez-Jimenez F, Muinos F, Sentis I, et al. A compendium of mutational cancer driver genes. Nat Rev Cancer. 2020 Oct;20(10):555–572.
   PubMed Web of Science ®Google Scholar
• Li K, Du Y, Li L, et al. Bioinformatics approaches for anti-cancer drug discovery. Curr Drug Targets. 2020;21(1):3–17.
   PubMed Web of Science ®Google Scholar
• Zhang M, Jang H, Nussinov R. PI3K inhibitors: review and new strategies. Chem Sci. 2020 Jun 21;11(23):5855–5865.
   PubMed Web of Science ®Google Scholar
• Gorelick AN, Sanchez-Rivera FJ, Cai Y, et al. Phase and context shape the function of composite oncogenic mutations. Nature. 2020 Jun;582(7810):100–103.
   PubMed Web of Science ®Google Scholar